poisar

Stocks · News reference

PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort

Benzinga Newsdesk

Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PEPG
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate

    PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same

    PEPG
  2. SEC EDGAR

    8-K filing — PepGen Inc. (PEPG)

    Filed: 2026-08-06 AccNo: 0001193125-26-336767 Size: 15 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    PEPG